source
- BioMarin to buy Alesta Therapeutics for $275M, adding rare bone disease drug to pipelineBioMarin announced Tuesday that it will acquire privately held Alesta Therapeutics, paying $275 million upfront with potential additional payments tied to milestones. The deal, expected to close b…
- Third patient dies in Chinese trial of RiboX Therapeutics' experimental genetic therapyA patient with an autoimmune disease died after receiving an experimental genetic medicine from RiboX Therapeutics, a Shanghai‑based biotech startup. The death marks the third fatality reported in…